During March – April 2024, Alligator Bioscience carried out a rights issue of units (the "Rights Issue"). Each unit issued in the Rights Issue consisted of one (1) ordinary share and one (1) warrant series TO 9. One (1) warrant series TO 9 entitles the holder to subscribe for one (1) new ordinary share in the Company. Upon full exercise of all warrants, Alligator Bioscience will receive approximately SEK 55.0 million before issue costs. 13 December 2024 is the last day of trading in warrants series TO 9.

Complete terms and conditions for the warrants are available on the Company's website, www.alligatorbioscience.com.

Summarized terms for warrants series TO 9
Exercise period: 4 December 2024 – 18 December 2024.
Subscription price: SEK 0.55 per share. The subscription price corresponds to 90 per cent of the volume-weighted average price of the Company's ordinary share on Nasdaq Stockholm during the period 4 – 29 November 2024.
Issue volume: 100,084,946 warrants series TO 9. For each warrant series TO 9, the holder can subscribe for one (1) new ordinary share in the Company. If all warrants are exercised, 100,084,946 ordinary shares will be issued, which will provide the Company with approximately SEK 55.0 million before issue costs.
Last day of trading in warrants series TO 9: 13 December 2024.
Share capital and dilution: Upon full exercise of all 100,084,946 warrants series TO 9, the share capital will increase by a maximum of SEK 80,067.9568 to SEK 687,259.2256 through the issuance of a maximum of 100,084,946 new ordinary shares, resulting in that the total number of outstanding shares in the Company will increase from 758,989,086 to 859,074,032, whereof 858,294,863 are ordinary shares and 779,169 are series C shares. Upon full exercise of all warrants series TO 9, the dilution of the ordinary shares amounts to approximately 11.7 per cent. The total number of votes in the Company will, following full exercise of all warrants TO 9, amount to 858,372,779.9.

Please note that the warrants series TO 9 that are not exercised by 18 December 2024, or sold by 13 December 2024, will expire without value. In order for the warrants not to lose their value, active subscription of shares or sale of warrants is required. Please note that some nominees may close their application earlier than 18 December 2024.

Advisers
Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the Rights Issue and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.